DOCSLIB.ORG

Thomas A. Ban Barry Blackwell, Samuel Gershon, Peter R. Martin, Gregers Wegener

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thomas A. Ban Barry Blackwell, Samuel Gershon, Peter R. Martin, Gregers Wegener International Network for the History of Neuropsychopharmacology Educational E-Books Thomas A. Ban Barry Blackwell, Samuel Gershon, Peter R. Martin, Gregers Wegener INHN 2014 Edited by Peter R. Martin International Network for the History of Neuropsychopharmacology Risskov 2015 2 Contents PREFACE ...................................................................................................................................... 10 HISTORICAL DICTIONARY IN NEUROPSYCHOPHARMACOLOGY ................................. 14 Active reflex by Joseph Knoll ................................................................................................ 16 Amine oxidase by Joseph Knoll............................................................................................. 17 Anna Monika Prize by Samuel Gershon ................................................................................ 18 Ataraxic drugs by Carlos R. Hojaij ........................................................................................ 19 Catecholaminergic activity enhancer effect by Joseph Knoll ................................................ 20 Component specific clinical trial by Martin M. Katz ............................................................ 21 Dahlem Conferences by Jules Angst ..................................................................................... 22 Delay’s classification by Carlos R. Hojaij ............................................................................. 23 Depressors of affect by Carlos R. Hojaij ............................................................................... 24 Depressors of vigilance by Carlos R. Hojaij .......................................................................... 25 Electroencephalogram by Antonio E. Nardi .......................................................................... 26 Endogenous enhancer regulation by Joseph Knoll ................................................................ 28 Endogenous enhancer substance by Joseph Knoll ................................................................. 29 Enhancer substance by Joseph Knoll ..................................................................................... 30 Glass-cylinder seeking drive by Joseph Knoll ....................................................................... 31 International Group for the Study of Affective Disorders (IGSAD) by Jules Angst ............. 33 Monoamine oxidase by Joseph Knoll .................................................................................... 34 Monoamine oxidase A by Joseph Knoll ................................................................................ 35 Monoamine oxidase B by Joseph Knoll ................................................................................ 36 Multivantaged assessment method by Martin M. Katz .......................................................... 37 National Advisory Committee on Psychopharmacology by Martin M. Katz ........................ 38 National Institute of Mental Health Collaborative Study by Martin M. Katz ........................ 39 Neuroleptics by Thomas A. Ban ............................................................................................ 40 Pharmacopsychology by Thomas A. Ban .............................................................................. 42 Psychoanaleptics by Carlos R. Hojaij .................................................................................... 44 Psychodysleptics by Carlos R. Hojaij .................................................................................... 45 Psycholeptic by Carlos R. Hojaij ........................................................................................... 46 Psychopharmacology by Thomas A. Ban .............................................................................. 47 Psychopharmacology Service Center by Martin M. Katz ...................................................... 49 Psychotropic Drugs by Thomas A. Ban ................................................................................. 50 Comments by Carlos R. Hojaij .............................................................................................. 51 Stimulants of affect by Carlos R. Hojaij ................................................................................ 52 3 Stimulants of vigilance by Carlos R. Hojaij .......................................................................... 53 Symposia Medica Hoechst by Jules Angst ............................................................................ 54 Tyramine oxidase by Joseph Knoll ........................................................................................ 55 PHOTO HISTORY OF NEUROPSYCHOPHARMACOLOGY .................................................. 56 Individual photos ....................................................................................................................... 58 Thomas A. Ban and Joseph Knoll (2002) – received fom Oakley S. Ray ............................. 58 Thomas A. Ban and Alfred Pletscher (2002) – received from Thomas A. Ban ..................... 59 Philip B. Bradley and Thomas A. Ban (2002) – received from Thomas A. Ban ................... 60 Roscoe Brady, Irwin J. Kopin, Frederick K. Goodwin and Julius Axelrod (1970) – received from Irwin J. Kopin ................................................................................................. 61 Aitor Castillo and Pedro Ruiz (2012) – received from Aitor Castillo ................................... 62 Leonard Cook (1991) – received from Leonard Cook ........................................................... 63 Edmundo Fisher (1974) – received from Carlos R. Hojaij .................................................... 64 Laurie Geffin, Alan Kopin, Lindor Brown and John Gillespie (1968) – received from Irwin J. Kopin ........................................................................................................................ 65 Joseph Knoll and Daniel Bovet (1969) – received from Joseph Knoll .................................. 66 Irwin Kopin, Burroughs Mider and Louis Sokoloff (1980) – received from Irwin J. Kopin 67 Lorna Sandler, Barbara Pare, C. Michael Pare, Jane Pare, Rita Kopin and Merton Sandler (1964) – received from Irwin J. Kopin .................................................................................. 68 Jerzy A.J. Vetulani, Chaim R. Belmaker, Per Bech, Paul Kielholz, Monika Rief Rheme and Irwin J. Kopin (1983) – received from Irwin J. Kopin .................................................... 69 Julius Axelrod’s 80th birthday celebrations (1992) – received from Irwin J. Kopin .............. 70 Photo collections ........................................................................................................................ 71 CINP COLLECTION: 1ST INTERNATIONAL CONGRESS (1958) ................................. 71 Leonard Cook and Joseph Brady – received from Leonard Cook ......................................... 71 2ND INTERNATIONAL CATECHOLAMINE SYMPOSIUM (1965) ............................... 72 Julius Axelrod, Rita Kopin, Irwin J. Kopin and George Hertting – received from Irwin J. Kopin .................................................................................................................................... 72 AMERICAN ACADEMY OF ARTS AND SCIENCES - NEURAL PROPERTIES OF THE BIOGENIC AMINES: NIMH NEUROSCIENCE RESEARCH PROGRAM WORK SESSION (1966) – received from Irwin J. Kopin ................................................................. 73 INTERNATIONAL SYMPOSIUM ON PHARMACOLOGY, TOXICOLOGY AND ABUSE OF PSYCHOTOMIMETICS (1968) ....................................................................... 74 Thomas A. Ban and Jacques Boissier – received from Simone Radouco-Thomas ............... 74 Jacques Boissier – received from Simone Radouco-Thomas ................................................ 75 Pierre Deniker – received from Simone Radouco-Thomas ................................................... 76 Daniel X. Freedman – received from Simone Radouco-Thomas .......................................... 77 4 Heinz E. Lehmann – received from Simone Radouco-Thomas ............................................. 78 Vincenzo G. Longo – received from Simone Radouco-Thomas ........................................... 79 Vincenzo G. Longo, Daniel X. Freedman and Corneille Radouco-Thomas – received from Simone Radouco-Thomas ............................................................................................. 80 Theodore Sourkes – received from Simone Radouco-Thomas .............................................. 81 Stephen Szara – received from Simone Radouco-Thomas .................................................... 82 WORKSHOP SECOND NEUROSCIENCE RESEARCH PROGRAM (1968) – received from Irwin J. Kopin ................................................................................................................ 83 CIBA FOUNDATION SYMPOSIUM: MONOAMINE OXIDASE AND ITS INHIBITION (1975) – received from Joseph Knoll .............................................................. 84 Hermann Blaschko, Joseph Knoll and Thomas Singer – received from Joseph Knoll .......... 85 KROC FOUNDATION CONFERENCE ON GABA (1975) – received from Irwin J. Kopin ..................................................................................................................................... 86 ACNP COLLECTION: ACNP ANNUAL MEETING (1992) .............................................. 87 Past Presidents of ACNP – received from Irwin J. Kopin ....................................................
Load more

Recommended publications
  • The Integrated Nature of Metamemory and Memory
    The Integrated Nature of Metamemory and Memory John Dunlosky and Robert A. Bjork Introduction Memory has been of interest to scholars and laypeople alike for over 2,000 years. In a rather gruesome example from antiquity, Cicero tells the story of Simonides (557– 468 BC), who discovered the method of loci, which is a powerful mental mnemonic for enhancing one’s memory. Simonides was at a banquet of a nobleman, Scopas. To honor him, Simonides sang a poem, but to Scopas’s chagrin, the poem also honored two young men, Castor and Pollux. Being upset, Scopas told Simonides that he was to receive only half his wage. Simonides was later called from the banquet, and legend has it that the banquet room collapsed, and all those inside were crushed. To help bereaved families identify the victims, Simonides reportedly was able to name every- one according to the place where they sat at the table, which gave him the idea that order brings strength to our memories and that to employ this ability people “should choose localities, then form mental images of things they wanted to store in their memory, and place these in the localities” (Cicero, 2001). Tis example highlights an early discovery that has had important applied impli- cations for improving the functioning of memory (see, e.g., Yates, 1997). Memory theory was soon to follow. Aristotle (385–322 BC) claimed that memory arises from three processes: Events are associated (1) through their relative similarity or (2) rela- tive dissimilarity and (3) when they co-occur together in space and time.
    [Show full text]
  • The Development Concept of “Endogenous Psychoses” Helmut Beckmann, MD; Hermann Jakob, MD; Dieter Senitz, MD
    Clinical research The development concept of “endogenous psychoses” Helmut Beckmann, MD; Hermann Jakob, MD; Dieter Senitz, MD Entorhinal region he entorhinal region is an outstanding, differ- T 1 entiated “association center” within the allocortex. It is intimately connected with the hippocampus by way of the perforant pathway. It thus forms, together with the hippocampus, a multineuronal regulatory circuit at the center of the limbic system. Signals arriving in the entorhinal cortex proceed to the hippocampus, pass Several structural deviances in the brain in “endogenous through several synapses, and return, in part, to the psychoses” have been described over the last decades. The entorhinal cortex. This regulatory circuit seems to be of enlargement of the lateral ventricles and the subtle struc- major importance for the storage of orientation and also tural deficits in temporobasal and orbital frontal struc- for memory.2 tures (hypofrontality) are reasonably well established in Studies in primates have shown that primary cortical the majority of schizophrenic patients. We examined the fields and all secondary cortical fields with visual, audi- cytoarchitecture of these important central structures, tory, and somatosensory functions have reciprocal con- namely the entorhinal region and the orbitofrontal cor- nections with the entorhinal cortex, either directly or by tex (Brodmann area 11), which have been under meticu- way of the perirhinal area.3-5 The multisensory areas in lous investigation in our laboratories over the last few caudal portions of the orbitofrontal region, and the ros- decades. In a new series of schizophrenic patients and nor- tral and ventral fields of the claustrocortex, project mal controls, we made serial cuts of the whole rostral mainly onto the rostral fields of the entorhinal area entorhinal cortex on both sides.
    [Show full text]
  • Peter Riederer
    Profiles (List of Publications) February 25, 2016 Peter Riederer 1 1992 (419) Frölich L, Riederer P (1992) Demenz vom Alzheimer-Typ: Biochemische Befunde und ätiologische Hypothesen. Therapiewoche 42 (9):500-505 (420) Riederer P, Lange KW, Kornhuber J, Danielczyk W (1992) Glutamatergic-Dopaminergic Balance in the Brain. Arzneim-Forsch/Drug Res 42 (I):265-268 (421) Gerlach M, Riederer P (1992) Biochemische Grundlagen der Psychosen. In: Der Medizinische Notfall VI. Proceedings, Interdisziplinäres Forum für Med. Fortbildung, Neuhofen/Ybbs, pp 65-71 (422) Riederer P, Laux G, Pöldinger W (1992) Neuro-Psychopharmaka, Bd. 1, SpringerVerlag WienNewYork (423) Berger W, Riederer P (1992) 10.2 Neurotransmitter-Regelkreise. Riederer P, Laux G, Pöldinger (eds) Neuro-Psychopharmaka, Bd. 1. Springer-Verlag WienNewYork, pp 225-271 (424) Müller WE, Riederer P, Kienzel E (1992) 9. Grundlegende Aspekte zur Neurotransmission. Riederer P, Laux G, Pöldinger (eds) Neuro-Psychopharmaka, Bd. 1. Springer-Verlag WienNewYork, pp 222-248 (425) Sofic E, Riederer P, Schmidt B, Fritze J, Kollegger H, Dierks T, Beckmann H (1992) Biogenic amines and metabolites in CSF from patients with HIV infection. Biogenic Amines 8 (5):293-298 (426) Riederer P, Lange KW (1992) Pathogenesis of Parkinson´s disease. Current Opinion in Neurology and Neurosurgery 5:295-300 (427) Gerlach M, Riederer P, Youdim MBH (1992) The molecular pharmacoloy of L-deprenyl. European Journal of Pharmacology - Molecular Pharmacology Section 226:97-108 (428) Hiemke C, Baumann P, Breyer-Pfaff U, Gold R, Klotz U, Müller-Oerlinghausen B, Rao M-L, Riederer P, Wetzel H, Wiedemann K (1992) Drug Monitoring in Psychiatric Patients: Which Approach is Useful to Improve Psychopharmacotherapy? Pharmacopsychiat 25:72-74 2 (429) Youdim MBH, Riederer P (1992) Iron in the Brain, and Parkinson´s Disease.
    [Show full text]
  • NIH Public Access Author Manuscript Pharmacol Ther
    NIH Public Access Author Manuscript Pharmacol Ther. Author manuscript; available in PMC 2010 August 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Pharmacol Ther. 2009 August ; 123(2): 239±254. doi:10.1016/j.pharmthera.2009.04.002. Ethnobotany as a Pharmacological Research Tool and Recent Developments in CNS-active Natural Products from Ethnobotanical Sources Will C. McClatcheya,*, Gail B. Mahadyb, Bradley C. Bennettc, Laura Shielsa, and Valentina Savod a Department of Botany, University of Hawaìi at Manoa, Honolulu, HI 96822, U.S.A b Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612, U.S.A c Department of Biological Sciences, Florida International University, Miami, FL 33199, U.S.A d Dipartimento di Biologia dì Roma Trè, Viale Marconi, 446, 00146, Rome, Italy Abstract The science of ethnobotany is reviewed in light of its multidisciplinary contributions to natural product research for the development of pharmaceuticals and pharmacological tools. Some of the issues reviewed involve ethical and cultural perspectives of healthcare and medicinal plants. While these are not usually part of the discussion of pharmacology, cultural concerns potentially provide both challenges and insight for field and laboratory researchers. Plant evolutionary issues are also considered as they relate to development of plant chemistry and accessing this through ethnobotanical methods. The discussion includes presentation of a range of CNS-active medicinal plants that have been recently examined in the field, laboratory and/or clinic. Each of these plants is used to illustrate one or more aspects about the valuable roles of ethnobotany in pharmacological research.
    [Show full text]
  • Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by William E. Bunney, Jr
    1 RECOLLECTIONS OF THE HISTORY OF NEUROPSYCHOPHARMACOLOGY THROUGH INTERVIEWS CONDUCTED BY WILLIAM E. BUNNEY, JR. Edited by Peter R. Martin International Network for the History of Neuropsychopharmacology Risskov 2016 2 William E. Bunney, Jr. (circa 1980) 3 Contents PREFACE ..................................................................................................................................................... 4 1. THOMAS A. BAN ............................................................................................................................... 9 2. ARVID CARLSSON .......................................................................................................................... 28 3. JOSEPH T. COYLE ............................................................................................................................ 38 4. ELLEN FRANK ................................................................................................................................. 55 5. J. CHRISTIAN GILLIN ..................................................................................................................... 66 6. LOUIS A. GOTTSCHALK ................................................................................................................ 78 7. SALOMON Z. LANGER ................................................................................................................... 89 8. HEINZ E. LEHMANN ....................................................................................................................
    [Show full text]
  • Quality Use of Medicines in Residential Aged Care
    RESEARCH Quality use of medicines in Michael Somers residential aged care Ella Rose Dasha Simmonds Claire Whitelaw Janine Calver Christopher Beer Background Approximately 190 000 people in high risk of ADEs in frail older people. For example, Older people are more likely to be Australia were estimated to have anticholinergic drugs commonly produce adverse exposed to polypharmacy. People dementia in 2006, with the prevalence effects in elderly people and are more likely to be with dementia, especially those living expected to increase to 465 000 by 2031.1 prescribed to people with dementia than those in residential aged care facilities The prevalence of dementia increases without.7 (RACFs), are at particularly high risk of with age, from 6.5% of Australians aged Antipsychotic medications are commonly used medication harm. We sought to describe medications prescribed for a sample of 65 years and over to 22% of Australians to manage the behavioural and psychological 2 people with dementia living in RACFs. aged 85 years and over. Dementia is symptoms of dementia (BPSD), such as associated with a large burden of disease psychosis, depression, agitation, aggression Methods in Australia’s aging population, costing and disinhibition.1,8 There is concern that A total of 351 residents with dementia Australia $1.4 billion in 2003.2 Most of this antipsychotics are used too frequently as a aged over 65 years were recruited from 36 RACFs in Western Australia. burden was associated with residential first line treatment for BPSD, with the risks of 2 Data on all medications prescribed aged care facilities (RACFs). Dementia antipsychotic use outweighing the benefits at their were collected, including conventional is the medical problem most frequently likely level of use.8 For example, risperidone, an medications, herbal medications, managed by general practitioners atypical antipsychotic prescribed frequently for the vitamins and minerals.
    [Show full text]
  • Health and Social Outcomes Associated with High-Risk Alcohol Use
    Manitoba Centre for Health Policy Health and Social Outcomes Associated with High-Risk Alcohol Use Summer 2018 Nathan C Nickel, MPH, PhD Jeff Valdivia, MNRM, CAPM Deepa Singal, PhD James Bolton, MD Christine Leong, PharmD Susan Burchill, BMus Leonard MacWilliam, MSc, MNRM Geoffrey Konrad, MD Randy Walld, BSc, BComm (Hons) Okechukwu Ekuma, MSc Greg Finlayson, PhD Leanne Rajotte, BComm (Hons) Heather Prior, MSc Josh Nepon, MD Michael Paille, BHSc This report is produced and published by the Manitoba Centre for Health Policy (MCHP). It is also available in PDF format on our website at: http://mchp-appserv.cpe.umanitoba.ca/deliverablesList.html Information concerning this report or any other report produced by MCHP can be obtained by contacting: Manitoba Centre for Health Policy Rady Faculty of Health Sciences Max Rady College of Medicine, University of Manitoba 4th Floor, Room 408 727 McDermot Avenue Winnipeg, Manitoba, Canada R3E 3P5 Email: [email protected] Phone: (204) 789-3819 Fax: (204) 789-3910 How to cite this report: Nathan C Nickel, James Bolton, Leonard MacWilliam, Okechukwu Ekuma, Heather Prior, Jeff Valdivia, Christine Leong, Geoffrey Konrad, Greg Finlayson, Josh Nepon, Deepa Singal, Susan Burchill, Randy Walld, Leanne Rajotte, Michael Paille. Health and Social Outcomes Associated with High-Risk Alcohol Use. Winnipeg, MB. Manitoba Centre for Health Policy, Summer 2018. Legal Deposit: Manitoba Legislative Library National Library of Canada ISBN 978-1-896489-90-2 ©Manitoba Health This report may be reproduced, in whole or in part, provided the source is cited. 1st printing (Summer 2018) This report was prepared at the request of Manitoba Health, Seniors and Active Living (MHSAL), a department within the Government of Manitoba, as part of the contract between the University of Manitoba and MHSAL.
    [Show full text]
  • Investigating the Roles of Memory and Metamemory in Trauma-Related Outcomes
    ABSTRACT A PTSD ANALOGUE STUDY: INVESTIGATING THE ROLES OF MEMORY AND METAMEMORY IN TRAUMA-RELATED OUTCOMES Ban Hong (Phylice) Lim, Ph.D. Department of Psychology Northern Illinois University, 2016 Michelle M. Lilly, Director Trauma survivors who develop posttraumatic stress disorder (PTSD) often display symptoms of memory fragmentation such as an impaired ability to recall trauma memories. These observations are consistent with prominent theories of PTSD, which consider memory fragmentation as a central feature of PTSD. Correspondingly, most empirically supported interventions for PTSD focus on addressing dysfunctional thoughts and behaviors and integrating fragmented memories of the event. More recently, this assumption has been challenged by research indicating that metamemory – one’s subjective beliefs about one’s memory functioning and quality – may partially account for reported memory fragmentation among individuals with PTSD. Memory underconfidence, regardless of whether or not it is founded or wholly accurate, may lead to feelings of anxiety, especially in the process of recalling and making sense of one’s trauma memory. Despite the intertwined nature of their relationship, the association between memory and metamemory has been understudied in the trauma literature. This dissertation investigated whether PTSD is a disorder of memory fragmentation, perceived memory fragmentation, or both by examining the association between memory and metamemory. A trauma analogue between-subjects experimental design was employed. Eighty- four healthy participants were randomly assigned to receive either positive feedback or negative feedback after completing a standardized memory assessment. Despite the use of randomization, the manipulation groups systematically differed on both baseline memory ability and baseline memory confidence. Contrary to the first hypothesis, after controlling for the effect of baseline metamemory beliefs, the groups did not differ on their recall task performance, F(1,80) = .34, p = .56.
    [Show full text]
  • Jean Delay Preamble
    1 Barry Blackwell: Pioneers and Controversies in Psychopharmacology Chapter Six: Jean Delay Preamble Jean Delay is perhaps best remembered for the discovery of Chlorpromazine, the first effective drug for the treatment resistant psychotic men and women who filled the world’s asylums in the mid twentieth century. Compared to Delay’s other scientific and literary accomplishments, as told in Driss Moussai’s biography, his role in this discovery was largely conceptual and clinically modest, but as was customary in hierarchical French academia, Delay’s name came first on scientific publications. The clinical work was conducted by Pierre Deniker and an intern in his department, J.M. Harl, who died prematurely in a mountain climbing accident. Deniker described the early work in detail (Deniker, 1970) when he received the Taylor Manor Award for the discovery and presented his paper, “Introduction of Neuroleptic Chemotherapy.” “Logically a new drug was tried in cases resistant to all existing therapies. We had scarcely treated 10 patients - with all due respect to fervent adherents of statistics - when our conviction proved correct. It was supported by the sudden, great interest of nursing personnel, who had always been reserved about innovations.” When the first paper was presented to the French Medico-Psychological Society at a meeting on shock or sleep therapy the effect was described as ”neuroleptic” – effecting the neuron - in cases of “manic excitation, and more generally, psychotic patients who were often resistant to shock or sleep therapy.” The specific effects were noted on “agitation, aggressiveness and delusive conditions of schizophrenia which improved. Contact with patients could be re-established, but deficiency symptoms did not change markedly.” When six definitive papers were published between May and June 1952 these observations had been made on only 38 patients without any attempt at controlled design (Delay, Deniker and Harl 1952).
    [Show full text]
  • ANNUAL REPORT 1981-1982 Montreal Neurological Hospital Montreal Neurological Institute
    VAll ANNUAL REPORT 1981-1982 Montreal Neurological Hospital Montreal Neurological Institute 47th Annual Report Montreal Neurological Hospital Montreal Neurological Institute 1981-1982 (Version francaise disponible sur demande.) Table of Contents Montreal Neurological Hospital Neurogenetics 86 Board of the Corporation 7 Neuromuscular Research 89 Board of Directors 8 Neuro-ophthalmology 91 Council of Physicians Executive 10 Neuropharmacology 92 Clinical and Laboratory Staff 12 Research Computing 94 Consulting and Visiting Staff 17 William Cone Laboratory 95 Professional Advisors 19 Resident and Rotator Staff 20 Education Clinical and Laboratory Fellows 21 Clinical Training Opportunities 101 Nursing Administration and Courses of Instruction 105 Education 23 Post-Basic Nursing Program 107 Graduates of Post-Basic Nursing Program 25 Publications 111 Administrative Staff 26 Supervisory Officers 26 Finances Executive of the Friends of the Neuro Montreal Neurological Hospital 127 27 Montreal Neurological Institute 131 Clergy 27 Endowments 132 Grants for Special Projects 133 Montreal Neurological Institute MNI Grants 135 Neurosciences Advisory Council 31 Donations 136 Advisory Board 32 Suggested Forms for Bequests 139 Scientific Staff 34 Academic Appointments, McGill 36 Statistics Executive Committee 40 Classification of Operations 143 Research Fellows 41 Diagnoses 146 Causes of Death 147 Director's Report 45 Hospital Reports Neurology 53 Neurosurgery 55 Council of Physicians 57 Nursing 59 Administration 62 Finance 64 Social Work 65 Institute Reports El El Experimental Neurophysiology 74 Fellows' Library 77 Muscle Biochemistry 78 Neuroanatomy 80 Neurochemistry 82 Montreal Neurological Hospital In April 1983 Dr. William Feindel, director of the Montreal Neurological Institute and director-general of the Montreal Neurological Hospital was named an officer of the Order of Canada.
    [Show full text]
  • Transposition, 6 | 2016 Copying Machines 2
    Transposition Musique et Sciences Sociales 6 | 2016 Lignes d’écoute, écoute en ligne Copying machines Unconscious musical plagiarism and the mediatisation of listening and memory John Shiga Electronic version URL: http://journals.openedition.org/transposition/1569 DOI: 10.4000/transposition.1569 ISSN: 2110-6134 Publisher CRAL - Centre de recherche sur les arts et le langage Electronic reference John Shiga, « Copying machines », Transposition [Online], 6 | 2016, Online since 20 March 2017, connection on 30 July 2019. URL : http://journals.openedition.org/transposition/1569 ; DOI : 10.4000/ transposition.1569 This text was automatically generated on 30 July 2019. La revue Transposition est mise à disposition selon les termes de la Licence Creative Commons Attribution - Partage dans les Mêmes Conditions 4.0 International. Copying machines 1 Copying machines Unconscious musical plagiarism and the mediatisation of listening and memory John Shiga 1 Introduced into musical copyright discourse in the early twentieth century, the notion of cryptomnesia or unconscious plagiarism highlights a key tension in copyright law. On the one hand, copyright acts as a recognizing authority for claims to authorship and originality, thus providing economic incentives to authors whose work is “original,” which in turn encourages cultural innovation. On the other hand, copyright facilitates ownership and control of cultural works by institutions rather than by authors, since its minimal notion of “originality” and extended period of protection encourage the production
    [Show full text]
  • American Psychiatric Press Review of Should Be Highly Interactive
    1998 SCIENTIFIC PROGRAM COMMITTEE Seated (left to right): Drs. Butterfield, Panzer, Winstead, Muskin, Reifler, Balon. 1st Row Standing (left to right): Drs. Pena, McDowell, Levin, Mega, Shafii, Ishiki, Spitz, Millman, Clark, Goldfinger. 2nd Row Standing (left to right): Drs. Lu, Wick, Ratner, Belfec Hendren, Tamminga, Book, Freebury. 3rd Row Standing (left to right): Drs. Skodol, Greiner, Cutler, Weissman, Schneider, Hamilton. May 30,1998 Dear Colleagues and Guests: Welcome to the 151st Annual Meeting of the American Psychiatric Association. The theme for this meeting, which reflects our determination, vision and concern for every sector of American psychiatry, is: New Challenges for Proven Values: Defending Access, Fairness, Ethics, Decency As we work hard to build a better future for our patients, including children, minorities, the elderly and their families, there are some fundamentals we must keep in mind. Indeed, much of the scientific program addresses these issues. There are sessions on confidentiality, psychiatric education, ethics, the doctor/patient relationship, private practice, economics and managed care, as well as many excellent sessions on the latest developments in research and clinical practice. Two special "Days of Creation" have been planned for Monday and Tuesday, during which several sessions will highlight creativity. On Wednesday, selected sessions will examine "A Time of Violence." I am delighted that our international registration has grown so considerably over the past several years. That so many colleagues from around the world attend our Annual Meeting is a tribute to its high quality and diversity. At this meeting we will have a number of outstanding international guests, including leaders from the World Psychiatric Association, some of whom will make presentations and many of whom will represent their organizations at the Opening Session.
    [Show full text]